HSPB8 and amyotrophic lateral sclerosis: HSPB8 in increasing levels is being explored as an ALS therapeutic in a phase II clinical trial of colchicine (NCT03693781), which is known to enhance the expression of HSPB8 and several other proteins involved in autophagy as well as exhibiting anti-inflammatory properties113.